

Supplemental Online Content

Vardeny O, Vaduganathan M, Claggett BL, et al. Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. *JAMA Cardiol*. Published online November 17, 2024. doi:10.1001/jamacardio.2024.4539

eFigure 1. Patient Flow


eTable 1. Patients experiencing postrandomization potassium levels above 5.5 mmol/l

eTable 2. Patients Experiencing postrandomization Potassium Levels below 3.5 mmol/l

eFigure 2. Rates of cardiovascular death or total worsening heart failure across a range of time-updated potassium levels postrandomization by treatment

This supplemental material has been provided by the authors to give readers additional information about their work.

eFigure 1. Patient Flow



eTable 1. Patients experiencing post-randomization potassium levels above 5.5 mmol/l

	No potassium >5.5 mmol/L n=5203	Any potassium >5.5 mmol/L n=633	
Age	72.0 ± 9.7	71.6 ± 9.2	p=0.37
Women	2382 (45.8%)	255 (40.3%)	p=0.009
<u>Race</u>			p<0.001
Asian	908 (17.5%)	65 (10.3%)	
Black	78 (1.5%)	8 (1.3%)	
Other	155 (3.0%)	23 (3.6%)	
White	4062 (78.1%)	537 (84.8%)	
<u>Region</u>			p=0.33
Asia	895 (17.2%)	65 (10.3%)	
Eastern Europe	2233 (42.9%)	356 (56.2%)	
Latin America	556 (10.7%)	69 (10.9%)	
North America	410 (7.9%)	46 (7.3%)	
Western Europe, Oceania and Others	1109 (21.3%)	97 (15.3%)	
Any prior HF Hospitalization	3094 (59.5%)	404 (63.8%)	p=0.035
<u>Recency of Heart Failure Event</u>			p=0.59
<= 7 days from randomization	1021 (19.6%)	145 (22.9%)	
>7 days - <= 3 months	1776 (34.1%)	191 (30.2%)	
>3 months or no index HF event	2406 (46.2%)	297 (46.9%)	
Baseline Systolic Blood Pressure (mmHg)	129.3 ± 15.4	130.4 ± 14.4	p=0.10
Baseline Body Mass Index (kg/m ²)	30.0 ± 6.1	29.6 ± 5.7	p=0.18
Baseline Creatinine (mg/dL)	1.1 ± 0.3	1.2 ± 0.5	p<0.001
Baseline eGFR (mL/min/1.73m ²)	62.8 ± 19.7	57.6 ± 19.4	p<0.001
Baseline eGFR < 60 mL/min/1.73m ²	2428 (46.7%)	368 (58.1%)	p<0.001
Baseline UACR (mg/g)	18 [7 , 63]	22 [8 , 102]	p<0.001
Baseline potassium (mmol/L)	4.3 ± 0.5	4.7 ± 0.5	p<0.001
Baseline LVEF (%)	52.6 ± 7.8	52.1 ± 7.7	p=0.10
Baseline NT-proBNP (pg/mL)	1014 [441 , 1901]	1163 [501 , 2344]	p<0.001
<u>NYHA class</u>			p=0.19
NYHA class II	3623 (69.6%)	424 (67.0%)	
NYHA class III	1543 (29.7%)	207 (32.7%)	
NYHA class IV	36 (0.7%)	2 (0.3%)	
History of Hypertension (N)	4603 (88.5%)	574 (90.7%)	p=0.10
Diabetes Mellitus at baseline	2059 (39.6%)	320 (50.6%)	p<0.001

Atrial fibrill. at baseline electrocardiogram	1995 (38.3%)	231 (36.5%)	p=0.37
History of Stroke	617 (11.9%)	68 (10.7%)	p=0.41
Any prior HF Hospitalization	3094 (59.5%)	404 (63.8%)	p=0.035
History of myocardial infarction	1318 (25.3%)	195 (30.8%)	p=0.003
Beta blocker	4415 (84.9%)	553 (87.4%)	p=0.09
ACEI	1856 (35.7%)	249 (39.3%)	p=0.07
ARB	1813 (34.8%)	237 (37.4%)	p=0.20
ARNI	448 (8.6%)	46 (7.3%)	p=0.25
Calcium channel blockers	1704 (32.8%)	216 (34.1%)	p=0.49
SGLT-2 inhibitor	717 (13.8%)	79 (12.5%)	p=0.37
Loop diuretic	4532 (87.1%)	562 (88.8%)	p=0.23
Digoxin	405 (7.8%)	56 (8.8%)	p=0.35
Potassium supplement	645 (12.4%)	49 (7.7%)	p<0.001
Randomized to finerenone (vs. placebo)	2495 (48.0%)	426 (67.3%)	p<0.001

eTable 2. Patients Experiencing post-randomization Potassium Levels below 3.5 mmol/l

	No potassium <3.5 mmol/L (after treatment start) n=5392	Any potassium <3.5 mmol/L (after treatment start) n=444	
Age	71.9 ± 9.6	72.3 ± 10.5	p=0.37
Women	2410 (44.7%)	227 (51.1%)	p=0.009
<u>Race</u>			p<0.001
Asian	845 (15.7%)	128 (28.8%)	
Black	77 (1.4 %)	9 (2.0 %)	
Other	169 (3.1 %)	9 (2.0 %)	
White	4301 (79.8%)	298 (67.1%)	
<u>Region</u>			p=0.15
Asia	836 (15.5%)	124 (27.9%)	
Eastern Europe	2457 (45.6%)	132 (29.7%)	
Latin America	582 (10.8%)	43 (9.7 %)	
North America	417 (7.7 %)	39 (8.8 %)	
Western Europe, Oceania and Others	1100 (20.4%)	106 (23.9%)	
Any prior HF Hospitalization	3212 (59.6%)	286 (64.4%)	p=0.045
<u>Recency of Heart Failure Event</u>			p=0.12
<= 7 days from randomization	1075 (19.9%)	91 (20.5%)	
>7 days - <= 3 months	1800 (33.4%)	167 (37.6%)	
>3 months or no index HF event	2517 (46.7%)	186 (41.9%)	
Baseline Systolic Blood Pressure (mmHg)	129.4 ± 15.2	129.1 ± 16.3	p=0.61
Baseline Body Mass Index (kg/m ²)	30.0 ± 6.1	29.5 ± 6.4	p=0.09
Baseline Creatinine (mg/dL)	1.1 ± 0.4	1.1 ± 0.4	p=0.83
Baseline eGFR (mL/min/1.73m ²)	62.3 ± 19.6	61.1 ± 20.6	p=0.23
Baseline eGFR < 60 mL/min/1.73m ²	2574 (47.7%)	222 (50.0%)	p=0.36
Baseline UACR (mg/g)	18 [7 , 65]	21 [9 , 74]	p=0.012
Baseline potassium (mmol/L)	4.4 ± 0.5	4.0 ± 0.5	p<0.001
Baseline LVEF (%)	52.5 ± 7.8	53.4 ± 7.8	p=0.013
Baseline NT-PRO BNP (pg/mL)	1014 [438 , 1916]	1312 [616 , 2264]	p<0.001
<u>NYHA class</u>			p=0.17
NYHA CLASS II	3750 (69.6%)	297 (66.9%)	
NYHA CLASS III	1612 (29.9%)	138 (31.1%)	
NYHA CLASS IV	29 (0.5 %)	9 (2.0 %)	
History of Hypertension (N)	4777 (88.6%)	400 (90.1%)	p=0.34
Diabetes Mellitus at baseline	2218 (41.1%)	161 (36.3%)	p=0.045
Atrial fibrill. at BL electrocardiogram	2016 (37.4%)	210 (47.3%)	p<0.001

History of Stroke: Med Hist Checkbox	620 (11.5%)	65 (14.6%)	p=0.048
Any prior HF Hospitalization	3212 (59.6%)	286 (64.4%)	p=0.045
History of myocardial infarction (N)	1420 (26.3%)	93 (20.9%)	p=0.013
Beta blocker use at baseline	4607 (85.4%)	361 (81.3%)	p=0.019
ACEI use	1982 (36.8%)	123 (27.7%)	p<0.001
ARB use (w/o ARNI)	1905 (35.3%)	145 (32.7%)	p=0.26
ARNI use at baseline	447 (8.3 %)	47 (10.6%)	p=0.09
Calcium channel blockers use at bl.	1761 (32.7%)	159 (35.8%)	p=0.17
SGLT-2 inhib. use at baseline	743 (13.8%)	53 (11.9%)	p=0.28
Loop diuretic at baseline	4699 (87.1%)	395 (89.0%)	p=0.27
Digoxin use at baseline	428 (7.9 %)	33 (7.4 %)	p=0.70
Potassium supplement	623 (11.6%)	71 (16.0%)	p=0.005
Randomized treatment	2776 (51.5%)	145 (32.7%)	p<0.001

eFigure 2. Rates of cardiovascular death or total worsening heart failure across a range of time-updated potassium levels post-randomization by treatment

